AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26017658 — intervention group
Group type: EXPERIMENTAL
Intervention: AccuCirc device
Number of subjects: 0
Study 26017658 — intervention group
Group type: COMPARATOR
Intervention: Mogen clamp
Number of subjects: 0
Study 23649968 — intervention group
Group type: EXPERIMENTAL
Intervention: Limaçon shapes with varying curvature presented in various 3D orientations
Number of subjects: 0
Study 23649968 — intervention group
Group type: EXPERIMENTAL
Intervention: Elliptical hoops with flattened regions
Number of subjects: 0
Study 21187303 — intervention group
Group type: COMPARATOR
Intervention: Cow-milk formula (CMF)
Number of subjects: 0
Study 21187303 — intervention group
Group type: EXPERIMENTAL
Intervention: Extensively protein hydrolysate formula (PHF)
Number of subjects: 0
Study 19717853 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical insulin (10 units, 0.1 cc) applied twice daily
Number of subjects: 45
Study 19717853 — intervention group
Group type: COMPARATOR
Intervention: Placebo (1 cc saline 0.9% for each 10 cm2 of wound) applied twice daily
Number of subjects: 45
Study 18520804 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegafur-uracil (UFT) 200 mg/m2 twice daily from day 1 through 14 plus gemcitabine 900 mg/m2 on days 8 and 15, repeated every 3 or 4 weeks
Number of subjects: 40
Study 18520804 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegafur-uracil (UFT) and gemcitabine combination chemotherapy
Number of subjects: 40
Study 16290983 — intervention group
Group type: EXPERIMENTAL
Intervention: roxithromycin
Number of subjects: 327
Study 16290983 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 327
Study 12017502 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-minute massage
Number of subjects: 78
Study 12017502 — intervention group
Group type: COMPARATOR
Intervention: 10 minutes of quiet time with a massage therapist (Control)
Number of subjects: 78
Study 12017502 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol levels
Number of subjects: 78
Study 10223230 — intervention group
Group type: EXPERIMENTAL
Intervention: Microsatellite instability (MSI) testing using six microsatellite markers (D2S123, D3S1029, D3S1611, TP53, Mfd26, and Mfd36)
Number of subjects: 47
Study 10223230 — intervention group
Group type: EXPERIMENTAL
Intervention: Microsatellite instability (MSI) testing in tumors of the distal colon and rectum
Number of subjects: 47
Study 10223230 — intervention group
Group type: COMPARATOR
Intervention: Control group (no MSI testing mentioned)
Number of subjects: 47
Study 8527689 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of talinolol (30 mg)
Number of subjects: 12
Study 8527689 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of talinolol (50 mg)
Number of subjects: 12
Study 2550647 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 130
Study 2550647 — intervention group
Group type: COMPARATOR
Intervention: Captopril
Number of subjects: 130
Study 137218 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminophylline (0.24 g i.v.)
Number of subjects: 24
Study 137218 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol (0.4 mg)
Number of subjects: 24
Study 137218 — intervention group
Group type: EXPERIMENTAL
Intervention: Diprophylline (0.28 g i.v.)
Number of subjects: 24
Study 137218 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexoprenaline (0.005 mg i.v.)
Number of subjects: 24
Study 137218 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (0.08 mg)
Number of subjects: 24
Study 137218 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexoprenaline
Number of subjects: 24
Study 29451036 — intervention group
Group type: EXPERIMENTAL
Intervention: Chondroitin Sulfate (CS) 800 mg/day
Number of subjects: 604
Study 29451036 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg/day
Number of subjects: 604
Study 29451036 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 604
Study 27834579 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Tubing (RT)
Number of subjects: 14
Study 27834579 — intervention group
Group type: EXPERIMENTAL
Intervention: Wobble Board (WB)
Number of subjects: 14
Study 27834579 — intervention group
Group type: COMPARATOR
Intervention: Both RT and WB
Number of subjects: 14
Study 26671226 — intervention group
Group type: EXPERIMENTAL
Intervention: CHU9D instrument (utility-based HRQOL)
Number of subjects: 1334
Study 26671226 — intervention group
Group type: EXPERIMENTAL
Intervention: PedsQL instrument (general HRQOL)
Number of subjects: 1334
Study 26671226 — intervention group
Group type: EXPERIMENTAL
Intervention: Construct validity of CHU9D
Number of subjects: 1334
Study 24349496 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional supplementation (protein/energy/vitamins) among undernourished mothers
Number of subjects: 283
Study 24349496 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional supplementation (energy/vitamins or vitamins only)
Number of subjects: 283
Study 24349496 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional supplementation
Number of subjects: 283
Study 22003157 — intervention group
Group type: EXPERIMENTAL
Intervention: Agility and perturbation training with standard exercise therapy
Number of subjects: 183
Study 22003157 — intervention group
Group type: COMPARATOR
Intervention: Standard exercise therapy
Number of subjects: 183
Study 18433755 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral anti-diabetic agents
Number of subjects: 574
Study 18433755 — intervention group
Group type: COMPARATOR
Intervention: Insulin therapy
Number of subjects: 574
Study 18433755 — intervention group
Group type: COMPARATOR
Intervention: Non-diabetic controls
Number of subjects: 574
Study 18433755 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin therapy (in vitro)
Number of subjects: 574
Study 18433755 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin therapy (before and after treatment)
Number of subjects: 574
Study 16988562 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous sumatriptan (3 mg in 1 mL saline)
Number of subjects: 15
Study 16988562 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sumatriptan (50 mg twice daily for 1 week)
Number of subjects: 15
Study 16988562 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 15
Study 12636950 — intervention group
Group type: EXPERIMENTAL
Intervention: Docosahexaenoic acid (33 or 133 mg) supplementation from eggs until parturition
Number of subjects: 350
Study 12636950 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 350
Study 10825311 — intervention group
Group type: EXPERIMENTAL
Intervention: Ornipressin started at 1 IU/h
Number of subjects: 60
Study 10825311 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine started at 0.04 microg x kg(‐1) x min(‐1)
Number of subjects: 60
Study 10825311 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine started at 2 microg x kg(‐1) x min(‐1)
Number of subjects: 60
Study 10825311 — intervention group
Group type: COMPARATOR
Intervention: Control group (15 patients without hypotension)
Number of subjects: 60
Study 8851608 — intervention group
Group type: COMPARATOR
Intervention: Atevirdine alone (treatment B)
Number of subjects: 12
Study 8851608 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent administration of didanosine and atevirdine (treatment C)
Number of subjects: 12
Study 1531328 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotinamide
Number of subjects: 0
Study 1531328 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 6337198 — intervention group
Group type: EXPERIMENTAL
Intervention: Aqueous solution of mixed-grass extract
Number of subjects: 50
Study 6337198 — intervention group
Group type: EXPERIMENTAL
Intervention: Formaldehyde-modified mixed-grass extract (allergoid)
Number of subjects: 50
Study 6337198 — intervention group
Group type: COMPARATOR
Intervention: Histamine solution (placebo)
Number of subjects: 50
Study 30269312 — intervention group
Group type: EXPERIMENTAL
Intervention: Tafenoquine (TQ) 400 mg for 3 days
Number of subjects: 70
Study 30269312 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine (CQ) 1500 mg for 3 days then Primaquine (PQ) 15 mg for 14 days
Number of subjects: 70
Study 30269312 — intervention group
Group type: EXPERIMENTAL
Intervention: Tafenoquine (TQ)
Number of subjects: 70
Study 30269312 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine (CQ) / Primaquine (PQ)
Number of subjects: 70
Study 30055170 — intervention group
Group type: EXPERIMENTAL
Intervention: FOB-Gold (Sentinel, Milan, Italy)
Number of subjects: 42179
Study 30055170 — intervention group
Group type: COMPARATOR
Intervention: OC-Sensor (Eiken Chemical, Tokyo Japan)
Number of subjects: 42179
Study 30055170 — intervention group
Group type: EXPERIMENTAL
Intervention: FOB-Gold
Number of subjects: 42179
Study 30055170 — intervention group
Group type: COMPARATOR
Intervention: OC-Sensor
Number of subjects: 42179
Study 30055170 — intervention group
Group type: EXPERIMENTAL
Intervention: FOB-Gold vs OC-Sensor
Number of subjects: 42179
Study 27410490 — intervention group
Group type: EXPERIMENTAL
Intervention: ASP2408 3.0 mg/kg subcutaneously every 4 weeks
Number of subjects: 88
Study 27410490 — intervention group
Group type: EXPERIMENTAL
Intervention: ASP2408 3.0 mg/kg subcutaneously every 2 weeks
Number of subjects: 88
Study 27410490 — intervention group
Group type: EXPERIMENTAL
Intervention: ASP2408 (various doses)
Number of subjects: 88
Study 27410490 — intervention group
Group type: EXPERIMENTAL
Intervention: ASP2408
Number of subjects: 88
Study 24496491 — intervention group
Group type: EXPERIMENTAL
Intervention: Estimation task (duration of a presented sound)
Number of subjects: 0
Study 24496491 — intervention group
Group type: EXPERIMENTAL
Intervention: Estimation task (length of a travelled distance)
Number of subjects: 0
Study 24496491 — intervention group
Group type: EXPERIMENTAL
Intervention: Production task (terminate a sound after a specified duration)
Number of subjects: 0
Study 24496491 — intervention group
Group type: EXPERIMENTAL
Intervention: Production task (cover a specified distance)
Number of subjects: 0
Study 22237225 — intervention group
Group type: EXPERIMENTAL
Intervention: 16G needle
Number of subjects: 50
Study 22237225 — intervention group
Group type: COMPARATOR
Intervention: 18G needle
Number of subjects: 50
Study 22237225 — intervention group
Group type: COMPARATOR
Intervention: Both needles
Number of subjects: 50
Study 20402591 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin 2.0 g orally as a single dose
Number of subjects: 517
Study 20402591 — intervention group
Group type: COMPARATOR
Intervention: Benzathine penicillin G 2.4 million units intramuscularly
Number of subjects: 517
Study 20402591 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 517
Study 18024508 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes passport intervention
Number of subjects: 993
Study 18024508 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 993
Study 16444089 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal dilator strips
Number of subjects: 23
Study 16444089 — intervention group
Group type: EXPERIMENTAL
Intervention: Local decongestants
Number of subjects: 23
Study 16444089 — intervention group
Group type: EXPERIMENTAL
Intervention: Local decongestant followed by nasal dilator
Number of subjects: 23
Study 16444089 — intervention group
Group type: COMPARATOR
Intervention: Placebo strip
Number of subjects: 23
Study 16444089 — intervention group
Group type: COMPARATOR
Intervention: No application
Number of subjects: 23
Study 16444089 — intervention group
Group type: COMPARATOR
Intervention: Local decongestant followed by placebo strip
Number of subjects: 23
Study 11890175 — intervention group
Group type: EXPERIMENTAL
Intervention: Team-oriented training using cognitive mapping technique (n = 29)
Number of subjects: 420
Study 11890175 — intervention group
Group type: COMPARATOR
Intervention: Didactic, informational training (n = 23)
Number of subjects: 420
Study 11890175 — intervention group
Group type: COMPARATOR
Intervention: No-training control group (n = 17)
Number of subjects: 420
Study 11910671 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg isoflavone extract
Number of subjects: 37
Study 11910671 — intervention group
Group type: EXPERIMENTAL
Intervention: 160 mg isoflavone extract
Number of subjects: 37
Study 11910671 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 7729400 — intervention group
Group type: EXPERIMENTAL
Intervention: Latex gloves of 0.83 mm thickness
Number of subjects: 20
Study 7729400 — intervention group
Group type: COMPARATOR
Intervention: Thinner latex gloves (0.21 mm, 0.51 mm, 0.65 mm, 0.76 mm)
Number of subjects: 20
Study 7729400 — intervention group
Group type: COMPARATOR
Intervention: Bare hand
Number of subjects: 20
Study 2393283 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefprozil under fasting conditions
Number of subjects: 12
Study 2393283 — intervention group
Group type: COMPARATOR
Intervention: Cefprozil after food intake
Number of subjects: 12
Study 2393283 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefaclor under fasting conditions
Number of subjects: 12
Study 2393283 — intervention group
Group type: COMPARATOR
Intervention: Cefaclor after food intake
Number of subjects: 12
Study 7079142 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural morphine
Number of subjects: 20
Study 7079142 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous morphine
Number of subjects: 20
Study 31096724 — intervention group
Group type: EXPERIMENTAL
Intervention: SOC+C+P (chlorpromazine 12.5 mg BID + promethazine 12.5 mg BID or chlorpromazine 25 mg BID + promethazine 25 mg BID) for 2 weeks
Number of subjects: 64
Study 31096724 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC) treatment
Number of subjects: 64
Study 31096724 — intervention group
Group type: EXPERIMENTAL
Intervention: SOC+C+P
Number of subjects: 64
Study 29333947 — intervention group
Group type: EXPERIMENTAL
Intervention: DTaP-IPV-HB-PRP∼T
Number of subjects: 2
Study 29333947 — intervention group
Group type: EXPERIMENTAL
Intervention: DTaP-IPV-HB/PRP∼T
Number of subjects: 2
Study 26717552 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifetime cannabis use disorder (CUD)
Number of subjects: 273
Study 26717552 — intervention group
Group type: EXPERIMENTAL
Intervention: History of multiple psychiatric disorders
Number of subjects: 273
Study 26717552 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifetime alcohol use disorder
Number of subjects: 273
Study 26717552 — intervention group
Group type: EXPERIMENTAL
Intervention: More frequent attempts to quit smoking tobacco
Number of subjects: 273
Study 26717552 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower self‐efficacy about weight management after quitting smoking tobacco
Number of subjects: 273
Study 25386018 — intervention group
Group type: EXPERIMENTAL
Intervention: Human Patient Simulation (HPS)
Number of subjects: 174
Study 25386018 — intervention group
Group type: COMPARATOR
Intervention: Case-Based Learning (CBL)
Number of subjects: 174
Study 22563773 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfuzosin 10 mg once daily
Number of subjects: 130
Study 22563773 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study 20228981 — intervention group
Group type: EXPERIMENTAL
Intervention: Restorations with marginal beveling
Number of subjects: 13
Study 20228981 — intervention group
Group type: COMPARATOR
Intervention: Restorations without bevel (butt joint)
Number of subjects: 13
Study 17481803 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini-hystroscopy (Group A)
Number of subjects: 950
Study 17481803 — intervention group
Group type: COMPARATOR
Intervention: Traditional hystroscopy (Group B)
Number of subjects: 950
Study 16134997 — intervention group
Group type: EXPERIMENTAL
Intervention: Desloratadine (DL)
Number of subjects: 26
Study 16134997 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 11923030 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbal therapies
Number of subjects: 15000000
Study 9472506 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct offer of HIV testing
Number of subjects: 3024
Study 9472506 — intervention group
Group type: COMPARATOR
Intervention: Control group (no information or direct offer)
Number of subjects: 3024
Study 9472506 — intervention group
Group type: EXPERIMENTAL
Intervention: Information provided (leaflet and discussion)
Number of subjects: 3024
Study 9472506 — intervention group
Group type: EXPERIMENTAL
Intervention: General findings
Number of subjects: 3024
Study 7629460 — intervention group
Group type: EXPERIMENTAL
Intervention: Subscapular skinfold thickness (thinnest quartile)
Number of subjects: 323
Study 7629460 — intervention group
Group type: EXPERIMENTAL
Intervention: Subscapular skinfold thickness (fattest quartile)
Number of subjects: 323
Study 7629460 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum reported body mass index (highest quartile)
Number of subjects: 323
Study 7629460 — intervention group
Group type: EXPERIMENTAL
Intervention: Reported body mass index aged 21 years (highest quartile)
Number of subjects: 323
Study 7629460 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum reported body mass index and reported body mass index aged 21 years
Number of subjects: 323
Study 1973770 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based intervention including mass education about childhood pneumonia and case-management by trained health workers using co-trimoxazole.
Number of subjects: 10123
Study 32615 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacampicillin 1600 mg twice daily
Number of subjects: 48
Study 32615 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacampicillin 800 mg three times daily
Number of subjects: 48
Study 32615 — intervention group
Group type: COMPARATOR
Intervention: Oral ampicillin 1000 mg three times daily
Number of subjects: 48
Study 31064563 — intervention group
Group type: EXPERIMENTAL
Intervention: COPD self-management intervention
Number of subjects: 153
Study 31064563 — intervention group
Group type: EXPERIMENTAL
Intervention: Household member secondary outcomes
Number of subjects: 153
Study 31064563 — intervention group
Group type: EXPERIMENTAL
Intervention: Inclusion of household member QALYs in ICER
Number of subjects: 153
Study 28566169 — intervention group
Group type: EXPERIMENTAL
Intervention: DLPFC stimulation (2mA, 20min, anodal stimulation)
Number of subjects: 13
Study 28566169 — intervention group
Group type: EXPERIMENTAL
Intervention: M1 stimulation (2mA, 20min, anodal stimulation)
Number of subjects: 13
Study 28566169 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 13
Study 25986639 — intervention group
Group type: EXPERIMENTAL
Intervention: Booklet-based vestibular rehabilitation with expert telephone support
Number of subjects: 33
Study 25986639 — intervention group
Group type: COMPARATOR
Intervention: Booklet-based vestibular rehabilitation without expert telephone support
Number of subjects: 33
Study 23866694 — intervention group
Group type: EXPERIMENTAL
Intervention: High bicarbonate mineral water (SY)
Number of subjects: 12
Study 23866694 — intervention group
Group type: COMPARATOR
Intervention: Low mineral water (Control)
Number of subjects: 12
Study 21034681 — intervention group
Group type: EXPERIMENTAL
Intervention: ADHD group (n = 116)
Number of subjects: 262
Study 21034681 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 146)
Number of subjects: 262
Study 19821718 — intervention group
Group type: EXPERIMENTAL
Intervention: CUF2 herbal formula (0.619-g capsule daily for 6 months)
Number of subjects: 85
Study 19821718 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study 16423088 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 2 x 40 mg, levofloxacin 2 x 500 mg, and amoxicillin 2 x 1 g for 7 days (ELA)
Number of subjects: 61
Study 16423088 — intervention group
Group type: COMPARATOR
Intervention: Esomeprazole 2 x 20 mg, clarithromycin 2 x 500 mg, and amoxicillin 2 x 1 g for 7 days (ECA)
Number of subjects: 61
Study 16423088 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 61
Study 15233698 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole 10 mg on-demand treatment
Number of subjects: 535
Study 15233698 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 535
Study 11764011 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (30 or 60 mg)
Number of subjects: 989
Study 11764011 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 989
Study 10633220 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 IU/kg rhGH
Number of subjects: 32
Study 10633220 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 IU/kg rhGH
Number of subjects: 32
Study 10633220 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 32
Study 10633220 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 IU/kg rhGH and 0.5 IU/kg rhGH
Number of subjects: 32
Study 8866880 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 11
Study 8866880 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 1516463 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefetamet pivoxil 20 mg/kg b.i.d. for 7 days
Number of subjects: 148
Study 1516463 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefetamet pivoxil 20 mg/kg b.i.d. for 10 days
Number of subjects: 148
Study 1516463 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefetamet pivoxil 10 mg/kg b.i.d. for 10 days
Number of subjects: 148
Study 1516463 — intervention group
Group type: COMPARATOR
Intervention: Phenoxymethylpenicillin for 10 days
Number of subjects: 148
Study 6661468 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose naloxone infusion
Number of subjects: 12
Study 6661468 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose naloxone infusion
Number of subjects: 12
Study 6661468 — intervention group
Group type: COMPARATOR
Intervention: Saline control infusion
Number of subjects: 12
Study 30890120 — intervention group
Group type: EXPERIMENTAL
Intervention: As planned (n=98)
Number of subjects: 113
Study 30890120 — intervention group
Group type: EXPERIMENTAL
Intervention: Laggers (n=15)
Number of subjects: 113
Study 29095990 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-cholesterol, low-fat (LChF) diet
Number of subjects: 30
Study 29095990 — intervention group
Group type: COMPARATOR
Intervention: High-cholesterol, high-fat (HChF) diet
Number of subjects: 30
Study 26775262 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced goal setting linked to a structured incentive scheme (text messages and rewards for achieving goals)
Number of subjects: 570